{"id":4974,"date":"2010-11-18T22:15:51","date_gmt":"2010-11-19T03:15:51","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=4974"},"modified":"2011-07-19T17:44:42","modified_gmt":"2011-07-19T21:44:42","slug":"appraise-2-apixaban-in-acs-study-discontinued-due-to-increased-bleeding","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/11\/18\/appraise-2-apixaban-in-acs-study-discontinued-due-to-increased-bleeding\/","title":{"rendered":"APPRAISE-2 Apixaban in ACS Study Discontinued Due to Increased Bleeding"},"content":{"rendered":"<p><a href=\"http:\/\/www.businesswire.com\/news\/bms\/20101118007161\/en\/APPRAISE-2-Study-Investigational-Compound-Apixaban-Acute-Coronary\">Bristol-Myers Squibb announced on Thursday evening<\/a> the discontinuation of APPRAISE-2, the phase 3 trial comparing apixaban to placebo in patients with acute coronary syndrome. The decision was based on a recommendation from the data monitoring committee based on &#8220;a clinically important increase in bleeding among patients randomized to apixaban,&#8221; according to the company press release.<\/p>\n<p>Robert Harrington, co-chair of the APPRAISE-2 steering committee, said the decision should not impact the &#8220;promising results&#8221; in phase 3 trials of apixaban in patients with venous thromboembolism and atrial fibrillation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bristol-Myers Squibb announced on Thursday evening the discontinuation of APPRAISE-2, the phase 3 trial comparing apixaban to placebo in patients with acute coronary syndrome. The decision was based on a recommendation from the data monitoring committee based on &#8220;a clinically important increase in bleeding among patients randomized to apixaban,&#8221; according to the company press release. [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[495,1],"tags":[492,363],"class_list":["post-4974","post","type-post","status-publish","format-standard","hentry","category-anticoagulation-2","category-general","tag-anticoagulation","tag-apixaban"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/4974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=4974"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/4974\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=4974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=4974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=4974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}